Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 3, 2012, Pages 317-320

  Matsuzawa, Naoki ^a   Nakamura, Katsunori ^a   Matsuda, Masayuki ^a   Ishida, Fumihiro ^b   Ohmori, Shigeru ^a  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytochrome P450 2C19; Multiple myeloma; Polymorphism; Thalidomide

Indexed keywords

GENOMIC DNA; SAURAMIDE; THALED; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AMYLOIDOSIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYP2C19 GENE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPANESE; MALE; MORNING DOSAGE; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; POEMS SYNDROME; SOMNOLENCE;

AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, GENETIC; THALIDOMIDE;

EID: 84857874126     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.317     Document Type: Article

References (19)

1. Eriksson T, Björkman S, Höglund P. Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol., 57, 365-376 (2001).
2. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol., 109, 89-96 (2000).
3. Calabrese L, Resztak K. Thalidomide revisited: pharmacology and clinical applications. Expert Opin. Investig. Drugs, 7, 2043-2060 (1998).
4. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, O'Hara C, Fennessey S, Finn KT, Wright DG, Skinner M, Sanchorawala V. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin. Lymphoma, 3, 241-246 (2003).
5. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, 2949-2951 (2005).
6. Meyring M, Mühlbacher J, Messer K, Kastner-Pustet N, Bringmann G, Mannschreck A, Blaschke G. In vitro biotransformation of (R)- and (S)-thalidomide: application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites. Anal. Chem., 74, 3726-3735 (2002).
7. Teo SK, Sabourin PJ, O'Brien K, Kook KA, Thomas SD. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J. Biochem. Mol. Toxicol., 14, 140-147 (2000).
8. Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol. Ther., 1, 669-673 (2002).
9. Ando Y, Fuse E, Figg WD. Thalidomide metabolism by the CYP2C subfamily. Clin. Cancer Res., 8, 1964-1973 (2002).
10. Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, Joel SP, Malpas JS. s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol. J., 5, 247-254 (2004).
11. Knoche B, Blaschke G. Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography. J. Chromatogr. A, 666, 235-240 (1994).
12. Nishimura K, Hashimoto Y, Iwasaki S. (S)-Form of alpha-methyl-N(alpha)- phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem. Pharm. Bull., 42, 1157-1159 (1994).
13. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M, Kosuge K, Hanai H, Chiba K, Ishizaki T, Kaneko E. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin. Pharmacol. Ther., 66, 265-274 (1999).
14. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. Pharmacol. Chemother., 25, 324-337 (1965).
15. Murphy-Poulton SF, Boyle F, Gu XQ, Mather LE. Thalidomide enantiomers: determination in biological samples by HPLC and vancomycin-CSP. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 831, 48-56 (2006).
16. Sembongi K, Tanaka M, Sakurada K, Kobayashi M, Itagaki S, Hirano T, Iseki K. A new method for determination of both thalidomide enantiomers using HPLC systems. Biol. Pharm. Bull., 31, 497-500 (2008).
17. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol., 46, 594-598 (1994).
18. Fujita Y, Yamamoto K, Aomori T, Murakami H, Horiuchi R. Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies. Yakugaku Zasshi, 128, 1449-1457 (2008), Japanese.
19. Vangsted AJ, Søeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel U, Werge T, Rasmussen HB. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer, 10, 404-411 (2010).